Skip to main content

Table 2 The number of patients who achieved a ≥50% or ≥75% reduction in outcome measures following BOTOX treatment

From: Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

Outcome

≥50% reduction n (%)

≥75% reduction n (%)

Headache days

80/254 (32%)

36/254 (14%)

Migraine days

128/254 (50%)

58/254 (24%)

Mild days

70/254 (28%)

32/254 (13%)

Painkiller days

87/243 (36%)

47/243 (19%)

Triptan days

76/242 (31%)

36/242 (15%)

Days off work

30/58 (53%)

19/58 (29%)

 

≥2-fold increase n (%)

≥3-fold increase n (%)

Crystal clear days

128/254 (50%)

79/254 (31%)